A new blood thinner significantly lowers stroke risk in heart patients
In short: A study of 5,599 patients with atrial fibrillation found that a novel medication, apixaban, was more effective than aspirin at preventing strokes. The researchers focused on individuals who could not take standard vitamin K antagonist treatments, providing a critical alternative for a high-risk group.
The trial aimed to find a safer and more effective way to prevent systemic embolism in patients with specific heart rhythm issues. By comparing apixaban to aspirin over a mean follow-up of 1.1 years, the team observed a notable reduction in primary complications.
The study was a double-blind, randomized trial. While it showed clear benefits for stroke prevention, it is important to note that the study was terminated early due to the significant advantage observed in the apixaban group.
Why it matters: For patients unable to use standard anticoagulants, apixaban offers a potent way to lower stroke risk with a manageable safety profile.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Research: Connolly et al. (2011). Apixaban in Patients with Atrial Fibrillation. New England Journal of Medicine.
To cite this card, link to https://intellectplus.co.uk/app/health-research-a-new-blood-thinner-significantly-lowers-stroke-risk-in-hear.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Clinical trials · More in Health · Latest · A–Z · All topics
